Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Stifel Reiterates Buy Rating on Biogen (BIIB) Following Acquisition of HI-Bio
May 22, 2024 9:41 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $275.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "BIIB announced this morning plans to acquire Human Immunology Biosciences (HI-Bio) for $1.1B, with up to $650MM in potential milestone payments. This deal fits into... More
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-Bio
May 22, 2024 9:33 AM EDTPiper Sandler analyst Christopher Raymond reiterated an Overweight rating and $335.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Remain OW rated on BIIB shares after announcement of the acquisition of HI-Bio for $1.15B up-front plus $650M in milestone payments. Bottom line... More
Biogen in up to $1.8 billion deal as rare diseases take center stage
May 22, 2024 7:37 AM EDT(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.
Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary... More
Biogen (BIIB) to Acquire Human Immunology Biosciences for $1.15B Upfront Plus Milestone Payments
May 22, 2024 7:31 AM EDTBiogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.
HI-Bios lead asset, felzartamab, is a fully... More
